Table 4.
The treatment and outcome of HD patients infected with COVID-19 on admission to hospital.
| Treatment | |
|---|---|
| Mechanical ventilation | 31 (100) |
| Noninvasive (high flow) | 3 (9.7) |
| Noninvasive (face mask) | 28 (90.3) |
| Glucocorticoids | 2 (6.5) |
| Intravenous immunoglobulin | 3 (9.7) |
| Intravenous albumin | 3 (9.7) |
| Antibiotic treatment | 26 (83.9) |
| Levofloxacin injection | 5 (16.1) |
| Levofloxacin injection + moxifloxacin | 3 (9.7) |
| Levofloxacin + ceftezole | 1 (3.2) |
| Moxifloxacin | 9 (29) |
| Rocephin | 2 (6.5) |
| Cefoperazone sodium and sulbactam sodium | 4 (12.9) |
| Ceftazidime | 1 (3.2) |
| Cefoxitin | 1 (3.2) |
| Antiviral treatment | 17 (54.8) |
| Abider + oseltamivir + lopinavir and ritonavir combination | 1 (3.2) |
| Abider + oseltamivir | 3 (9.7) |
| Abider + lopinavir and ritonavir combination | 2 (6.5) |
| Abider + ribavirin | 1 (3.2) |
| Oseltamivir + ribavirin | 1 (3.2) |
| Oseltamivir | 3 (9.7) |
| Lopinavir and ritonavir combination | 4 (12.9) |
| Abider | 2 (6.5) |
| Antibiotic treatment + antiviral treatment | 15 (48.4) |
| Antihypertensive therapy | 28 (90.3) |
| Patients (n = 31) | |
| Comorbid conditions | |
| Any | 18 (58.1) |
| ARDS | 8 (25.8) |
| Acute heart failure | 7 (22.6) |
| Shock | 5 (16.1) |
| Gastrointestinal hemorrhage | 5 (16.1) |
| Septicemia | 1 (3.2) |
| Cardiac arrest | 1 (3.2) |
| CT finding | |
| Oblivious improvement | 2 (6.5) |
| Slightly improvement | 13 (41.9) |
| No difference | 3 (9.7) |
| Deterioration | 4 (12.9) |
| No review | 9 (29) |
| Time of admission remission | |
| No remission | 11 (35.5) |
| Remission (days) | 20 (64.5) |
| 1–4 | 4 (12.9) |
| 5–9 | 10 (32.3) |
| 10–14 | 5 (16.1) |
| 15 | 1 (3.2) |
| Clinical outcome | |
| Remained in hospital | 27 (87.1) |
| Discharged | 2 (6.5) |
| Died | 2 (6.5) |